Wedbush Analysts Boost Earnings Estimates for VYGR

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Wedbush boosted their Q2 2025 earnings per share estimates for shares of Voyager Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst Y. Zhong now expects that the company will earn ($0.31) per share for the quarter, up from their previous forecast of ($0.37). Wedbush currently has a "Outperform" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics' Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.77) EPS.

Several other equities research analysts have also issued reports on the company. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Canaccord Genuity Group lowered their price target on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Voyager Therapeutics has an average rating of "Buy" and an average target price of $13.97.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR traded up $0.18 during trading hours on Friday, reaching $3.35. The stock had a trading volume of 662,542 shares, compared to its average volume of 446,728. The stock has a market cap of $185.30 million, a P/E ratio of 4.72 and a beta of 0.95. Voyager Therapeutics has a 12-month low of $2.75 and a 12-month high of $9.55. The stock has a 50 day simple moving average of $3.50 and a 200 day simple moving average of $4.89.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in Voyager Therapeutics in the 4th quarter valued at approximately $29,000. Tower Research Capital LLC TRC raised its holdings in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management raised its holdings in Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after purchasing an additional 2,444 shares during the period. CWM LLC raised its holdings in Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after purchasing an additional 9,376 shares during the period. Finally, Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics in the 4th quarter worth $60,000. Hedge funds and other institutional investors own 48.03% of the company's stock.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 10,885 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. This represents a 2.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 6.39% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.